First Trust Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.3M | Buy |
91,302
+47,402
| +108% | +$8.28M | 0.01% | 914 |
|
|
2025
Q4 | $7.46M | Sell |
43,900
-197,970
| -82% | -$30.4M | 0.01% | 1224 |
|
|
2025
Q3 | $31.9M | Buy |
241,870
+36,246
| +18% | +$4.35M | 0.02% | 751 |
|
|
2025
Q2 | $21.8M | Sell |
205,624
-57,893
| -22% | -$6.29M | 0.02% | 869 |
|
|
2025
Q1 | $32.7M | Sell |
263,517
-57,698
| -18% | -$7.53M | 0.03% | 703 |
|
|
2024
Q4 | $39.6M | Sell |
321,215
-15,812
| -5% | -$1.86M | 0.03% | 628 |
|
|
2024
Q3 | $37.5M | Buy |
337,027
+102,339
| +44% | +$11.2M | 0.04% | 599 |
|
|
2024
Q2 | $25M | Buy |
234,688
+98,666
| +73% | +$10.8M | 0.03% | 703 |
|
|
2024
Q1 | $16.4M | Buy |
136,022
+17,219
| +14% | +$2.11M | 0.02% | 865 |
|
|
2023
Q4 | $14.6M | Buy |
118,803
+64,340
| +118% | +$8.03M | 0.02% | 877 |
|
|
2023
Q3 | $7.05M | Buy |
54,463
+44,338
| +438% | +$5.91M | 0.01% | 1091 |
|
|
2023
Q2 | $1.26M | Sell |
10,125
-39,944
| -80% | -$5.37M | ﹤0.01% | 1911 |
|
|
2023
Q1 | $7.33M | Sell |
50,069
-16,002
| -24% | -$2.37M | 0.01% | 1068 |
|
|
2022
Q4 | $10.5M | Buy |
66,071
+62,016
| +1,529% | +$9.09M | 0.01% | 949 |
|
|
2022
Q3 | $541K | Sell |
4,055
-456
| -10% | -$69.3K | ﹤0.01% | 2175 |
|
|
2022
Q2 | $703K | Sell |
4,511
-75,533
| -94% | -$11.6M | ﹤0.01% | 2106 |
|
|
2022
Q1 | $12.5M | Buy |
80,044
+26,446
| +49% | +$3.84M | 0.01% | 973 |
|
|
2021
Q4 | $6.83M | Sell |
53,598
-110,552
| -67% | -$14.5M | 0.01% | 1217 |
|
|
2021
Q3 | $21.4M | Sell |
164,150
-19,689
| -11% | -$2.97M | 0.02% | 755 |
|
|
2021
Q2 | $32.7M | Buy |
183,839
+77,334
| +73% | +$13.4M | 0.04% | 590 |
|
|
2021
Q1 | $17.5M | Buy |
106,505
+59,670
| +127% | +$9.82M | 0.02% | 758 |
|
|
2020
Q4 | $7.73M | Sell |
46,835
-97,625
| -68% | -$14.5M | 0.01% | 926 |
|
|
2020
Q3 | $20.6M | Sell |
144,460
-82,526
| -36% | -$10.2M | 0.03% | 532 |
|
|
2020
Q2 | $25M | Sell |
226,986
-66,309
| -23% | -$7.33M | 0.04% | 494 |
|
|
2020
Q1 | $29.3M | Buy |
293,295
+68,992
| +31% | +$8.92M | 0.07% | 422 |
|
|
2019
Q4 | $33.5M | Buy |
224,303
+72,080
| +47% | +$9.81M | 0.06% | 474 |
|
|
2019
Q3 | $19.5M | Buy |
152,223
+27,373
| +22% | +$3.67M | 0.04% | 592 |
|
|
2019
Q2 | $17.8M | Sell |
124,850
-89,659
| -42% | -$12M | 0.03% | 604 |
|
|
2019
Q1 | $30.7M | Buy |
214,509
+61,424
| +40% | +$8.01M | 0.06% | 410 |
|
|
2018
Q4 | $19M | Buy |
153,085
+36,603
| +31% | +$5.43M | 0.05% | 520 |
|
|
2018
Q3 | $19.6M | Buy |
116,482
+93,748
| +412% | +$16.1M | 0.04% | 627 |
|
|
2018
Q2 | $3.92M | Buy |
22,734
+16,768
| +281% | +$2.74M | 0.01% | 1230 |
|
|
2018
Q1 | $901K | Buy |
+5,966
| New | +$875K | ﹤0.01% | 1825 |
|
|
2017
Q4 | – | Sell |
-14,310
| Closed | -$2.09M | – | 2424 |
|
|
2017
Q3 | $2.09M | Sell |
14,310
-352
| -2% | -$53.2K | 0.01% | 1437 |
|
|
2017
Q2 | $2.28M | Buy |
+14,662
| New | +$2.24M | 0.01% | 1397 |
|
|
2016
Q4 | – | Sell |
-17,487
| Closed | -$2.12M | – | 2466 |
|
|
2016
Q3 | $2.12M | Buy |
+17,487
| New | +$2.36M | 0.01% | 1302 |
|
|
2015
Q4 | – | Sell |
-214,295
| Closed | -$28.5M | – | 2270 |
|
|
2015
Q3 | $28.5M | Sell |
214,295
-817
| -0.4% | -$141K | 0.08% | 264 |
|
|
2015
Q2 | $37.9M | Buy |
215,112
+37,098
| +21% | +$6.66M | 0.1% | 219 |
|
|
2015
Q1 | $30.8M | Sell |
178,014
-87,074
| -33% | -$14.9M | 0.09% | 261 |
|
|
2014
Q4 | $43.4M | Sell |
265,088
-14,827
| -5% | -$2.46M | 0.15% | 160 |
|
|
2014
Q3 | $44.9M | Sell |
279,915
-47,750
| -15% | -$7.34M | 0.18% | 110 |
|
|
2014
Q2 | $48.2M | Sell |
327,665
-725
| -0.2% | -$101K | 0.2% | 95 |
|
|
2014
Q1 | $45.5M | Buy |
328,390
+10,127
| +3% | +$1.52M | 0.2% | 88 |
|
|
2013
Q4 | $40.3M | Sell |
318,263
-39,909
| -11% | -$4.13M | 0.2% | 96 |
|
|
2013
Q3 | $32.9M | Buy |
+358,172
| New | +$28.9M | 0.18% | 115 |
|
Other funds holding JAZZ
VPM
VCM
EC
First Trust Advisors's JAZZ Position: Q1 2026 in Review
First Trust Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 108% in Q1 2026, buying an estimated $8.28M and bringing the position to 91,302 shares worth $17.3M. The position accounts for 0.01% of the portfolio, ranked #914.
First Trust Advisors first reported a position in JAZZ in Q3 2013 and has held it in 45 quarters since. The position peaked at $48.2M in Q2 2014. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- First Trust Advisors held 91,302 shares of Jazz Pharmaceuticals worth $17.3M as of Q1 2026.
- First Trust Advisors bought 47,402 Jazz Pharmaceuticals shares in Q1 2026, an estimated $8.28M.
- Jazz Pharmaceuticals made up 0.01% of First Trust Advisors's portfolio in Q1 2026, its #914 holding.
- First Trust Advisors first reported a position in Jazz Pharmaceuticals in Q3 2013 and has held it in 45 quarters since.
- First Trust Advisors's Jazz Pharmaceuticals position peaked at $48.2M in Q2 2014.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.